Rob E. Aarnoutse

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse et al. · The Lancet Infectious Diseases · 2016 · 385 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

Rovina Ruslami, Ahmad Rizal Ganiem, Sofiati Dian et al. · The Lancet Infectious Diseases · 2012 · 352 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis

Martin J. Boeree, Andreas H. Diacon, Rodney Dawson et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 317 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

Hanneke M. J. Nijland, Rovina Ruslami, Janneke E. Stalenhoef et al. · Clinical Infectious Diseases · 2006 · 241 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8

The Pharmacokinetics and Pharmacodynamics of Pulmonary <i>Mycobacterium avium</i> Complex Disease Treatment

Jakko van Ingen, Eric F. Egelund, Adrah Levin et al. · American Journal of Respiratory and Critical Care Medicine · 2012 · 201 citations

Medicine, Infectious Diseases, Pharmacology +17